93 related articles for article (PubMed ID: 15349966)
1. In vitro absorption and secretory quotients: practical criteria derived from a study of 331 compounds to assess for the impact of P-glycoprotein-mediated efflux on drug candidates.
Thiel-Demby VE; Tippin TK; Humphreys JE; Serabjit-Singh CJ; Polli JW
J Pharm Sci; 2004 Oct; 93(10):2567-72. PubMed ID: 15349966
[TBL] [Abstract][Full Text] [Related]
2. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport.
Varma MV; Sateesh K; Panchagnula R
Mol Pharm; 2005; 2(1):12-21. PubMed ID: 15804173
[TBL] [Abstract][Full Text] [Related]
3. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
Troutman MD; Thakker DR
Pharm Res; 2003 Aug; 20(8):1210-24. PubMed ID: 12948019
[TBL] [Abstract][Full Text] [Related]
4. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.
Rautio J; Humphreys JE; Webster LO; Balakrishnan A; Keogh JP; Kunta JR; Serabjit-Singh CJ; Polli JW
Drug Metab Dispos; 2006 May; 34(5):786-92. PubMed ID: 16455806
[TBL] [Abstract][Full Text] [Related]
5. Kinetic analysis of human and canine P-glycoprotein-mediated drug transport in MDR1-MDCK cell model: approaches to reduce false-negative substrate classification.
Li J; Wang Y; Hidalgo IJ
J Pharm Sci; 2013 Sep; 102(9):3436-46. PubMed ID: 23558561
[TBL] [Abstract][Full Text] [Related]
6. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Mahar Doan KM; Humphreys JE; Webster LO; Wring SA; Shampine LJ; Serabjit-Singh CJ; Adkison KK; Polli JW
J Pharmacol Exp Ther; 2002 Dec; 303(3):1029-37. PubMed ID: 12438524
[TBL] [Abstract][Full Text] [Related]
7. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Sachs-Barrable K; Thamboo A; Lee SD; Wasan KM
J Pharm Pharm Sci; 2007; 10(3):319-31. PubMed ID: 17727795
[TBL] [Abstract][Full Text] [Related]
8. Rational use of in vitro P-glycoprotein assays in drug discovery.
Polli JW; Wring SA; Humphreys JE; Huang L; Morgan JB; Webster LO; Serabjit-Singh CS
J Pharmacol Exp Ther; 2001 Nov; 299(2):620-8. PubMed ID: 11602674
[TBL] [Abstract][Full Text] [Related]
9. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux.
Hayeshi R; Masimirembwa C; Mukanganyama S; Ungell AL
Eur J Pharm Sci; 2006 Sep; 29(1):70-81. PubMed ID: 16846720
[TBL] [Abstract][Full Text] [Related]
10. Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates.
Kwon H; Lionberger RA; Yu LX
Mol Pharm; 2004; 1(6):455-65. PubMed ID: 16028357
[TBL] [Abstract][Full Text] [Related]
11. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.
He H; Lyons KA; Shen X; Yao Z; Bleasby K; Chan G; Hafey M; Li X; Xu S; Salituro GM; Cohen LH; Tang W
Xenobiotica; 2009 Sep; 39(9):687-93. PubMed ID: 19569734
[TBL] [Abstract][Full Text] [Related]
12. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia.
Stephens RH; O'Neill CA; Warhurst A; Carlson GL; Rowland M; Warhurst G
J Pharmacol Exp Ther; 2001 Feb; 296(2):584-91. PubMed ID: 11160647
[TBL] [Abstract][Full Text] [Related]
13. Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model.
Gombar VK; Polli JW; Humphreys JE; Wring SA; Serabjit-Singh CS
J Pharm Sci; 2004 Apr; 93(4):957-68. PubMed ID: 14999732
[TBL] [Abstract][Full Text] [Related]
14. In vitro-in vivo correlation in P-glycoprotein mediated transport in intestinal absorption.
del Amo EM; Heikkinen AT; Mönkkönen J
Eur J Pharm Sci; 2009 Feb; 36(2-3):200-11. PubMed ID: 19063964
[TBL] [Abstract][Full Text] [Related]
15. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux.
Desai PV; Sawada GA; Watson IA; Raub TJ
Mol Pharm; 2013 Apr; 10(4):1249-61. PubMed ID: 23363443
[TBL] [Abstract][Full Text] [Related]
16. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.
Lee JS; Paull K; Alvarez M; Hose C; Monks A; Grever M; Fojo AT; Bates SE
Mol Pharmacol; 1994 Oct; 46(4):627-38. PubMed ID: 7969041
[TBL] [Abstract][Full Text] [Related]
17. Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux.
Panchagnula R; Bansal T; Varma MV; Kaul CL
Pharmazie; 2005 Dec; 60(12):922-7. PubMed ID: 16398269
[TBL] [Abstract][Full Text] [Related]
18. Development of an improved three-dimensional in vitro intestinal mucosa model for drug absorption evaluation.
Li N; Wang D; Sui Z; Qi X; Ji L; Wang X; Yang L
Tissue Eng Part C Methods; 2013 Sep; 19(9):708-19. PubMed ID: 23350801
[TBL] [Abstract][Full Text] [Related]
19. The impact of protein on Caco-2 permeability of low mass balance compounds for absorption projection and efflux substrate identification.
Liu T; Chang LJ; Uss A; Chu I; Morrison RA; Wang L; Prelusky D; Cheng KC; Li C
J Pharm Biomed Anal; 2010 Apr; 51(5):1069-77. PubMed ID: 20036089
[TBL] [Abstract][Full Text] [Related]
20. Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs.
Fossati L; Dechaume R; Hardillier E; Chevillon D; Prevost C; Bolze S; Maubon N
Int J Pharm; 2008 Aug; 360(1-2):148-55. PubMed ID: 18539418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
